Clinical trial
Effect of Irbesartan on Insulin Sensitivity in Chronic Heart Failure
NCT00347087 · Charite University, Berlin, Germany, Other · Completed
Key facts
| NCT number | NCT00347087 |
|---|---|
| Title | Effect of Irbesartan on Insulin Sensitivity in Chronic Heart Failure |
| Official title | Effect of the Angiotensin II Receptor Antagonist Irbesartan on Insulin Sensitivity and Metabolic Profile in Patients With Chronic Heart Failure |
| Lead sponsor | Charite University, Berlin, Germany, Other |
| Collaborators | Bristol-Myers Squibb Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Chronic Heart Failure |
| Intervention type | Drug |
| Interventions | Irbesartan |
| Enrollment | 36 |
| Start date | Jul 1, 2004 |
| Completion | Jun 1, 2007 |
| First posted | Jul 4, 2006 |
| Last update posted | Oct 31, 2007 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: